[en] Naratriptan is a novel, potent agonist at the 5HT1B/1D receptor. A total of 335 migraine patients were treated in this randomized, double-blind, placebo-controlled, dose-ranging, in-clinic study, to evaluate the efficacy, safety and tolerability of five doses of subcutaneous (sc) naratriptan (0.5, 1, 2.5, 5 or 10 mg) in comparison with sc sumatriptan (6 mg) and placebo in the acute treatment of a moderate/severe migraine attack. Headache relief [reduction of headache severity from moderate or severe (grade 2/3) to mild or none (grade 1/0)] at 1 and 2 h after each dose, was reported by a statistically significantly higher proportion of patients for all doses of sc naratriptan and sc sumatriptan (6 mg) than for placebo. The percentages of patients with headache relief at 2 h post-dose were: naratriptan (0.5 mg) 65%, (1 mg) 75%, (2.5 mg) 83%, (5 mg) 94% and (10 mg) 91%; sumatriptan (6 mg) 89%; placebo 41%, (P < 0.005). The earliest report of a statistically significant difference compared with placebo for the times assessed was with sc naratriptan (10 mg) at 10 min post-dose (P = 0.023). The percentages of patients reporting adverse events were dose-related; sc naratriptan (0.5 mg) 33%, (1 mg) 29%, (2.5 mg) 43%, (5 mg) 59% and (10 mg) 71%; sc sumatriptan 53%; placebo 22%. There were no clinically significant changes in electrocardiogram (ECG), vital signs or laboratory parameters. Systemic exposure increased proportionally to the dose, the absorption of sc naratriptan was rapid (tmax = 10 min) and the half-life was 5 h. In conclusion, sc naratriptan was an effective and well-tolerated acute treatment for migraine. Copyright 1998 Lippincott Williams & Wilkins
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Dahlof, C.
Hogenhuis, L.
Olesen, J.
Petit, H.
Ribbat, J.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Boswell, D.
Fuseau, E.
Hassani, H.
Winter, P.
Language :
English
Title :
Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.
Connor, H.E., O'Shaughnessy, C.T., Fenuik, W., Perren, M.J., North, P.C., Oxford, A.W., GR85548: A potent selective agonist for the intracranial vascular 5-HT1 receptor (1993) Br J Pharmacol, 108 (PROC SUPPL.), pp. 99P
Ferrari, M.D., 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists (1997) Neurology, 48 (3 SUPPL.), pp. S21-S24
Fuseau, E., Baille, P., Kempsford, R.D., A study to determine the absolute oral bioavailability of naratriptan (1997) Cephalalgia, 17 (3), pp. 07-A15
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain (1988) Cephalalgia, 8, pp. 1-96
Kempsford, R.D., Lacey, L.F., Keene, O.N., Thomas, M., The safety, tolerability and pharmacokinetics of subcutaneous GR85548, a novel 5-HT1 receptor agonist for the treatment of migraine (1993) Br J Clin Pharmacol, 36, pp. 17P
Klassen, A., Elkind, A., Asgharnejad, M., Webster, C., Laurenza, A., Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study (1997) Headache, 37 (10), pp. 640-645. , Naratriptan S2WA3001 Study Group
Mathew, N.T., Asgharnejad, M., Peykamian, M., Laurenza, A., Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study (1997) Neurology, 49 (6), pp. 1485-1490. , The Naratriptan S2WA3003 Study Group
McCullagh, P., Neider, J.A., (1983) Generalised Linear Models, pp. 101-126. , London: Chapman and Hall
Pilgrim, A.J., Blakeborough, P., The clinical efficacy of sumatriptan in the acute treatment of migraine (1994) Rev Contemporary Pharmacotherapy, 5 (4), pp. 295-309
Plosker, G.L., McTavish, D., Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache (1994) Drugs, 47, pp. 622-651
Ryan, R., Elkind, A., Baker, C.C., Mullican, W., DeBussey, S., Asgharnejad, M., Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies (1997) Neurology, 49 (5), pp. 1225-1230
Simmons, V.E., Blakeborough, P., The safety profile of sumatriptan (1994) Rev Contemporary Pharmacotherapy, 5 (4), pp. 319-328
Visser, W.H., Terwindt, G.M., Reines, S.A., Jiang, K., Lines, C.R., Ferrari, M.D., Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study (1996) Arch Neurol, 53 (11), pp. 1132-1137